Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 5
2004 6
2005 6
2006 13
2007 16
2008 15
2009 2
2010 9
2011 10
2012 6
2013 5
2014 5
2015 3
2016 5
2017 4
2018 1
2019 4
2020 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

114 results
Results by year
Filters applied: . Clear all
Page 1
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, Martinez-Lemus L, Manrique-Acevedo CM, Hayden MR, Duta C, Nistala R, Mayoux E, Padilla J, Chandrasekar B, DeMarco VG. Aroor AR, et al. Among authors: hayden mr. Cardiovasc Diabetol. 2018 Jul 30;17(1):108. doi: 10.1186/s12933-018-0750-8. Cardiovasc Diabetol. 2018. PMID: 30060748 Free PMC article.
Atherogenic dyslipidemia.
Hayden MR. Hayden MR. J Cardiometab Syndr. 2006 Summer;1(3):166-7. J Cardiometab Syndr. 2006. PMID: 17679821 No abstract available.
Insulin resistance and blood pressure.
Addison S, Stas S, Hayden MR, Sowers JR. Addison S, et al. Among authors: hayden mr. Curr Hypertens Rep. 2008 Aug;10(4):319-25. doi: 10.1007/s11906-008-0059-1. Curr Hypertens Rep. 2008. PMID: 18625163 Review.
Redox imbalance in diabetes.
Hayden MR, Sowers JR. Hayden MR, et al. Antioxid Redox Signal. 2007 Jul;9(7):865-7. doi: 10.1089/ars.2007.1640. Antioxid Redox Signal. 2007. PMID: 17477794 No abstract available.
114 results